DrugPatentWatch Database Preview
Details for Patent: 10,195,375
Which drugs does patent 10,195,375 protect, and when does it expire?
Patent 10,195,375 protects AIRDUO DIGIHALER, AIRDUO RESPICLICK, and ARMONAIR RESPICLICK, and is included in two NDAs.
This patent has fifty-eight patent family members in twenty-seven countries.
Summary for Patent: 10,195,375
| Title: | Airflow adaptor for a breath-actuated dry powder inhaler |
| Abstract: | An airflow adaptor for a breath-actuated dry powder inhaler. The airflow adaptor includes a conduit having a proximal end and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, and wherein the airflow adaptor further includes provisions for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor. |
| Inventor(s): | Blair; Julian Alexander (Stradbally, IE), Buck; Daniel (Waterford, IE), Hazenberg; Jan Geert (Kilkenny, IE), Zeng; Xian-Ming (London, GB) |
| Assignee: | NORTON HEALTHCARE LIMITED (West Yorkshire, GB) |
| Application Number: | 15/270,160 |
|
Patent Claim Types: see list of patent claims | Delivery; |
Drugs Protected by US Patent 10,195,375
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-004 | Jul 12, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-005 | Jul 12, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-006 | Jul 12, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-001 | Jan 27, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,195,375
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0919465.5 | Nov 6, 2009 |
International Family Members for US Patent 10,195,375
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010314369 | Start Trial | |||
| Australia | 2014201778 | Start Trial | |||
| Australia | 2017204342 | Start Trial | |||
| Brazil | 112012010354 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
